{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:00:10Z","timestamp":1775804410608,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the prevalence of antiphospholipid antibodies (aPLs) in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their impact on maternal-fetal outcomes, with an emphasis on gestational stage-specific differences and lupus anticoagulant (LAC) positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational cohort study was conducted at the Department of Obstetrics, Peking University People\u2019s Hospital, from December 2022 to January 2023. Eligible participants were singleton pregnant women without pre-existing pregnancy complications who tested positive for SARS-CoV-2. Serum samples were collected 2\u20134 weeks post-infection for testing of aPLs, including LAC, anti-\u03b22-glycoprotein I (a\u03b22GPI), and anticardiolipin antibodies. Maternal and fetal outcomes were monitored according to standard prenatal care protocols, with specific attention to placental dysfunction related complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall prevalence of aPLs in pregnant women infected with SARS-CoV-2 was 18.75%. All positive cases were single-antibody positive, either for a\u03b22GPI or LAC, with no instances of multiple antibody co-positivity. The prevalence of aPLs was significantly correlated with the gestational stage at the time of infection, rising from 5.88% in the first trimester to 16.00% in the second trimester and 26.31% in the third trimester (\n                      <jats:italic>P&amp;lt;0.05<\/jats:italic>\n                      ). Notably, all LAC-positive cases (constituting 8.25% of total infections) were exclusive to women infected during the third trimester. The group with aPLs positive status experienced a significantly higher incidence of placental dysfunction related complications, such as gestational hypertension, oligohydramnios, and fetal growth restriction, compared to the aPLs-negative group (60.00% vs. 29.23%,\n                      <jats:italic>P=0.036<\/jats:italic>\n                      ). The LAC-positive subgroup exhibited an even higher incidence of complications (71.43%,\n                      <jats:italic>P=0.037<\/jats:italic>\n                      ), with numerically higher complication rates observed in LAC-positive cases than other aPLs. Univariate logistic regression analysis revealed that aPLs positivity (\n                      <jats:italic>P=0.030<\/jats:italic>\n                      ) and specifically LAC positivity (\n                      <jats:italic>P=0.041<\/jats:italic>\n                      ) were independent risk factors for placental dysfunction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SARS-CoV-2 infection during pregnancy significantly increases the prevalence of aPLs, with a pattern that is dependent on the gestational stage. Positivity for aPLs, particularly LAC, is an independent risk factor for complications related to placental dysfunction. Our findings suggest that pregnant women infected with SARS-CoV-2, especially those in the third trimester, should undergo aPLs screening 2\u20134 weeks post-infection, along with enhanced monitoring for placental dysfunction, there should be vigilant surveillance of infection status, coagulation function, and appropriate obstetric management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1810392","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:04:54Z","timestamp":1775801094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiphospholipid antibody production in pregnant women with SARS-CoV-2 infection and its impact on maternal and fetal outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Shenglong","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus anticoagulant and abnormal coagulation tests in patients with covid-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","article-title":"Frequency and clinical correlates of antiphospholipid antibodies arising in patients with sars-cov-2 infection: findings from a multicentre study on 122 cases","volume":"38","author":"Gatto","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with covid-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.41409","article-title":"Anticardiolipin igg autoantibody level is an independent risk factor for covid-19 severity","volume":"72","author":"Bertin","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8408","article-title":"Coronavirus disease 2019 (covid-19) infection associated with antiphospholipid antibodies and four-extremity deep vein thrombosis in a previously healthy female","volume":"12","author":"Sung","year":"2025","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3876","article-title":"Prothrombotic autoantibodies in serum from patients hospitalized with covid-19","volume":"12","author":"Zuo","year":"2020","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001580","article-title":"Antiphospholipid antibodies in covid-19: a meta-analysis and systematic review","volume":"7","author":"Taha","year":"2025","journal-title":"RMD Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004849","article-title":"Maternal and perinatal outcomes associated with the omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection","volume":"140","author":"Seasely","year":"2022","journal-title":"Obstetrics Gynecology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00079-6","article-title":"Effects of the covid-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis","volume":"9","author":"Chmielewska","year":"2021","journal-title":"Lancet Global Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e009495","DOI":"10.1136\/bmjgh-2022-009495","article-title":"Adverse maternal, fetal, and newborn outcomes among pregnant women with sars-cov-2 infection: an individual participant data meta-analysis","volume":"8","author":"Smith","year":"2023","journal-title":"BMJ Global Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gocm.2023.05.001","article-title":"A spectrum of pathological changes induced by sars-cov-2: an observational study in a cohort of pregnant women from mizoram, India","volume":"3","author":"Vanremmawii","year":"2023","journal-title":"Gynecol Obstet Clin Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ajog.2016.03.001","article-title":"Placental origins of adverse pregnancy outcomes: potential molecular targets: an executive workshop summary of the eunice kennedy shriver national institute of child health and human development","volume":"215","author":"Ilekis","year":"2016","journal-title":"Am J Obstetrics Gynecology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953043","article-title":"Frequency of positive antiphospholipid antibodies in pregnant women with sars-cov-2 infection and impact on pregnancy outcome: a single-center prospective study on 151 pregnancies","volume":"13","author":"Gozzoli","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069739","article-title":"Diagnosis and management of covid-19 in pregnancy","volume":"377","author":"Nana","year":"2022","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3969\/j.issn.1007-8134.2023.01.02","article-title":"Diagnosis and treatment protocol for novel coronavirus infection (10th edition)","volume":"36","year":"2023","journal-title":"Infect Dis Inf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1044\/2020_AJSLP-20-00163","article-title":"Assessment, diagnosis, and treatment of dysphagia in patients infected with sars-cov-2: a review of the literature and international guidelines","volume":"29","author":"Vergara","year":"2020","journal-title":"Am J Speech-Language Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-0378(97)00059-4","article-title":"Antiphospholipid antibodies and reproduction","volume":"35","author":"Kutteh","year":"1997","journal-title":"J Reprod Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-199406000-00002","article-title":"Antiphospholipid antibodies in pregnancy: prevalence and clinical associations","volume":"49","author":"Pattison","year":"1994","journal-title":"Obstetrical Gynecological Survey"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104442","DOI":"10.1016\/j.jri.2025.104442","article-title":"Does covid-19 infection or covid-19 mrna vaccination induce antiphospholipid antibodies in women with recurrent pregnancy loss","volume":"168","author":"Takeshita","year":"2025","journal-title":"J Reprod Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103206","article-title":"Covid-19 and the antiphospholipid syndrome","volume":"21","author":"Serrano","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1097\/AOG.0000000000002923","article-title":"Thromboembolism in pregnancy: correction","volume":"132","year":"2018","journal-title":"Obstetrics Gynecology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"173\u2013","DOI":"10.1097\/01.aoa.0000719440.84472.52","article-title":"Coronavirus disease 2019 (covid-19) and pregnancy: what obstetricians need to know","volume":"40","author":"Rasmussen","year":"2020","journal-title":"Obstetric Anesth Digest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0049-3848(96)00176-4","article-title":"Blood clotting activation during normal pregnancy","volume":"84","author":"Comeglio","year":"1996","journal-title":"Thromb Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:04:55Z","timestamp":1775801095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1810392"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1810392","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1810392"}}